Virtual Library

Start Your Search

S. Otsuka



Author of

  • +

    MINI 04 - Clinical Care of Lung Cancer (ID 102)

    • Event: WCLC 2015
    • Type: Mini Oral
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      MINI04.11 - Incidence of Brain Metastasis in Non-Small Cell Lung Cancer Over Eleven Years at a Single Canadian Institution (ID 1585)

      17:45 - 17:50  |  Author(s): S. Otsuka

      • Abstract
      • Presentation
      • Slides

      Background:
      The highest percentage of metastasis to the brain exists among non-small cell lung cancer (NSCLC) patients. The exact incidence of brain metastasis (BM) in NSCLC is unknown, but current literature suggests that incidence for this cohort is increasing as cancer patients live longer. To date, only a single Canadian study reporting BM occurrence in lung cancer patients is available. A key limitation to this study is the method of incidence reporting, as number of cases, rather than number of cases as a percentage among lung cancer population. Reliable estimates of BM in NSCLC patients are necessary to further improve patient care and resource allocation.

      Methods:
      The Alberta Cancer Registry dataset was used to identify all NSCLC patients living in southern Alberta who are consulted at the Tom Baker Cancer Centre, Calgary, Alberta, Canada between 1999 and 2010. These patients were registered and their charts were reviewed for an institutional lung cancer database (Glans-Look Database). NSCLC patients were categorized into two groups: (i) having BM at diagnosis or (ii) developing BM between diagnosis and death. Patient characteristics were compared to the database NSCLC cohort and all metastatic cases. The number of BM cases was reported for each group per year. Incidence was calculated as a percentage of the NSCLC and metastatic disease cases, where applicable. Linear trend testing was performed.

      Results:
      A total of 5297 NSCLC patients were consulted. The percentage of BM at diagnosis in the cohort was 11% in 1999 and 8% in 2010 (linear trend test p-value=0.010). These numbers were 26% in 1999 and 15% in 2010 (p=0.010) in the metastatic cohort. The percentage of BM developed by death in the NSCLC cohort was 20% in 1999 and 13% in 2010 (p=0.010). These numbers were 44% in 1999 and 26% in 2010 (p=0.009) in the metastatic cohort (Figure 1). Out of 2501 non-metastatic NSCLC patients, 46% developed BM by death in 1999 compared to 62% in 2010 (p=0.14).

      Conclusion:
      Although the absolute number of NSCLC patients with BM at diagnosis has increased between 1999 and 2010, the incidence, reported as a percentage of the all NSCLC cases, is decreasing. Similar trends were not observed for non-metastatic patients. As a future step, a pre-specified multivariable analyses will be conducted to examine effects of age, gender, histology, smoking, and treatment on rates of BM in NSCLC.Figure 1



      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Biology, Pathology, and Molecular Testing
    • Presentations: 1
    • +

      P3.04-073 - CXCR4 Expression Is Associated with Poor Survival in Early, Resected NSCLC (ID 3081)

      09:30 - 09:30  |  Author(s): S. Otsuka

      • Abstract
      • Slides

      Background:
      CXCR4, a G protein coupled chemokine receptor, and its ligand, stromal cell derived factor-1 (SDF-1), play a critical role in organ specific tumor metastasis. In vitro, CXCR4 expression has been shown to correlate with migration, invasion and adhesion in various cancer cell lines including lung, breast and colon, among others. In clinical studies, patients whose tumors exhibit high CXCR4 expression tend to have a poorer clinical outcome. We previously demonstrated that high expression of CXCR4 by quantitative IHC in a cohort of 170 stage IV NSCLC specimens was associated with significantly decreased overall survival, particularly in the female patients. We subsequently investigated whether CXCR4 also conferred a poorer prognosis in our early stage NSCLC patients with resected disease, to validate our previous findings.

      Methods:
      After ethical approval was obtained, demographic details, clinical variables and outcome data were gathered on patients diagnosed at the Tom Baker Cancer Centre (TBCC) from 2003 to 2006. Formalin-fixed paraffin embedded tumor specimens were obtained from those patients diagnosed with resected stage I, II or III NSCLC and tissue micro arrays (TMAs) were generated. CXCR4 expression in NSCLC cells was analyzed by immunohistochemistry using anti CXCR4 mAb and the HistoRx PM-2000 platform, then correlated with clinical outcome. Statistical analysis was performed using the Kaplan-Meier method, multivariate analysis and a multi-state model to account for the competing risks of disease free and overall survival.

      Results:
      Of 1502 patients diagnosed with NSCLC at the TBCC in 2003-2006, 166 had resected (pneumonectomy, lobectomy or wedge resection) stage I (63%), II (30.7%) or III (9.6%) disease. 37.3% of the patients received adjuvant treatment (combined chemoradiotherapy or radical radiotherapy alone) after their surgery. 46.4% of the patients were still alive at the time of analysis. The mean CXCR4 AQUA scores were significantly lower for the early stage patients than those obtained for the advanced stage IV patients (1715.90 vs 2512.44 p< 0.0001). High CXCR4 expression was associated with worse overall survival (p = 0.026) but had no significant effect on disease free survival after resection (p = 0.376). Subgroup analysis showed no significant differences between genders in the association between high CXCR4 expression and clinical outcome.

      Conclusion:
      CXCR4 is expressed in early stage resected NSCLC tumors and appears to increase significantly from stage I-III to stage IV NSCLC. High CXCR4 expression is associated with significantly poorer overall survival in early stage resected patients, validating our previous findings in stage IV NSCLC using the same method. CXCR4 does not seem to be associated with disease free survival in this cohort of patients, nor does there seem to be any association between gender and the effect of CXCR4 on poor outcome unlike that seen in our stage IV NSCLC patients.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.